报告题目：Fully Synthetic Vaccines and Immune Modulators

报告人：Prof. Geert-Jan Boons, UGA Foundation Distinguished Professor in Biochemical Sciences, Complex Carbohydrate Research Center (CCRC)/Department of Chemistry, The University of Georgia

报告时间：2015年9月25日(星期五)，上午10:00-11:30

报告地点：上海市四平路1239号太阳成集团化学馆241室

报告人简介：

Dr. Boons received his M.Sc. in Chemistry in 1987 and his Ph.D. in Synthetic Carbohydrate Chemistry in 1991 from the State University of Leiden in The Netherlands. Prior to joining the faculty at the CCRC in 1998, he spent seven years in the United Kingdom, first as a postdoctoral fellow at Imperial College, London, and the University of Cambridge, and then as a lecturer and professor at the University of Birmingham. In 2003, Dr. Boons was awarded the Carbohydrate Research Award for Creativity in Carbohydrate Science by the European Carbohydrate Association, and was elected chairman for the 2005 Gordon Research Conference on Carbohydrates. In 2004, Dr. Boons received the Horace Isbell Award by the Division of Carbohydrate Chemistry of the American Chemical Society and was appointed Franklin Professor of Chemistry in the College of Arts and Sciences at the University of Georgia. In 2012, he received the Creative Research Inventor’s Award by the University of Georgia Research Foundation and was appointed UGA Foundation Distinguished Professor in Biochemical Sciences in the Franklin College of Arts and Sciences at the University of Georgia. He has been awarded by the International Carbohydrate Organization the Roy L. Whistler International Award in Carbohydrate Chemistry for 2014.

Abstract:We employ well-defined complex synthetic oligosaccharides and glycoconjugates to probe biological processes and use the resulting information to devise novel therapeutic strategies for various diseases. For example, we have designed, chemical synthesized and immunologically evaluated a number of fully synthetic vaccine candidates to establish strategies to overcome the poor immunogenicity of tumor-associated carbohydrates and glycopeptides. It has been found that a glycosylated MUC1 derived glycopeptide covalently linked to a Toll-like receptor (TLR) agonist can elicit potent humoral and cellular immune responses and is efficacious in reversing tolerance and generating a therapeutic response. The examination of a number of control compounds demonstrate that the therapeutic effect of the three-component vaccine is due to nonspecific antitumor responses elicited by the adjuvant, and specific humoral and cellular immune responses elicited by the MUC1 derived glycopeptide. It has been found that glycosylation of the MUC1 peptide is critical for inducing optimal responses and furthermore, it is essential that the helper T- and B-epitope are covalently attached to the TLR ligand. To identify new tumor associated carbohydrate antigens, 4-dibenzocyclooctynol derivatives have been developed as novel click reagents for the isolation and visualization of oligosaccharides of living cells that are metabolically labeled with azido containing monosaccharides. The new reagent has been used for the development of a quantitative glycoproteomics approach.